65,437 trials
Diabetes Mellitus, Type 2 · Hypertension
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to TEAEs — 3; 3; 2; 4 Participants
Epilepsy
Primary: Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) — 76; 49 events…
Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population — 15.9; 21.3 Percentage of participants…
Diabetes Mellitus
Primary: USS Virginia Time Within Target — 78.3; 71.4 percentage of time spent in range
Major Depressive Disorder · Soft Tissue Discomfort Syndrome · Pain
Primary: 24-hour Activity Level
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment — 0.174…
ADA-SCID · Adenosine Deaminase Deficiency · Severe Combined Immunodeficiency
Primary: Number of Patients Detoxified At Each Visit in EZN-2279 Treatment Period — 6; 6; 6; 5 Participants
Depression
Primary: Change in Serotonin Transporter Availability
Oxidative Stress
Primary: Difference in Resting Levels of Endogenous Antioxidant Proteins in Skeletal Muscle - Superoxide Dismutase 2 (SOD-2) — 0.42; 0.68 Arbitrary Units
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Hematological Malignancy
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 0; 0 Participants
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
Chemotherapy-induced Nausea and Vomiting
Primary: Number of Participants With Treatment-emergent AEs at Cycle 1 — 121; 122 Participants
Opiate Dependence
Primary: Relapse to Opioid Use in Subjects by Month 3 — 16; 20 Participants — p=0.38
Filariasis
Primary: Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events — 5; 6; 6; 4 Participants